1. Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood
2012;119:5980–8.
2. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M,
Juliusson G, et al. The European LeukemiaNet AML Working Party
consensus statement on allogeneic HSCT for patients with AML in
remission: an integrated-risk adapted approach. Nat Rev Clin Oncol
2012;9:579–90.
3. Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY,
Aleinikova O, et al. Improved outcome in pediatric relapsed acute
myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol
2013;31:599–607.
4. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST,
Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a
distinct HOX gene expression pattern. Blood 2011;118:3645–56.
5. de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, et al.
Pediatric non-Down syndrome acute megakaryoblastic leukemia is
characterized by distinct genomic subsets with varying outcomes.
Nat Genet 2017;49:451–6.
6. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK,
et al. Cytogenetics of childhood acute myeloid leukemia: United
Kingdom Medical Research Council Treatment trials AML 10 and 12.
J Clin Oncol 2010;28:2674–81.
7. Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al.
The molecular landscape of pediatric acute myeloid leukemia reveals
recurrent structural alterations and age-specific mutational interactions. Nat Med 2018;24:103–12.
8. Stratmann S, Yones SA, Mayrhofer M, Norgren N, Skaftason A,
Sun J, et al. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. Blood Adv 2021;5:
900–12.
9. Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR,
et al. Genomic profiling of pediatric acute myeloid leukemia reveals
a changing mutational landscape from disease diagnosis to relapse.
Cancer Res 2016;76:2197–205.
10. McNeer NA, Philip J, Geiger H, Ries RE, Lavallee VP, Walsh M, et al.
Genetic mechanisms of primary chemotherapy resistance in pediatric
acute myeloid leukemia. Leukemia 2019;33:1934–43.
11. Borel C, Dastugue N, Cances-Lauwers V, Mozziconacci MJ, Prebet T,
Vey N, et al. PICALM-MLLT10 acute myeloid leukemia: a French
cohort of 18 patients. Leuk Res 2012;36:1365–9.
12. Noort S, Zimmermann M, Reinhardt D, Cuccuini W, Pigazzi M,
Smith J, et al. Prognostic impact of t(16;21)(p11;q22) and t(16;21)
(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study
Group. Blood 2018;132:1584–92.
13. Liu Y, Li C, Shen S, Chen X, Szlachta K, Edmonson MN, et al. Discovery of regulatory noncoding variants in individual cancer genomes by
using cis-X. Nat Genet 2020;52:811–8.
14. Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM,
Erpelinck C, et al. A single oncogenic enhancer rearrangement
causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell
2014;157:369–81.
15. Schwartz JR, Ma J, Kamens J, Westover T, Walsh MP, Brady SW, et al.
The acquisition of molecular drivers in pediatric therapy-related
myeloid neoplasms. Nat Commun 2021;12:985.
16. Montefiori LE, Bendig S, Gu Z, Chen X, Polonen P, Ma X, et al.
Enhancer hijacking drives oncogenic BCL11B expression in lineageambiguous stem cell leukemia. Cancer Discov 2021;11:2846–67.
17. Tosi S, Mostafa Kamel Y, Owoka T, Federico C, Truong TH, Saccone S.
Paediatric acute myeloid leukaemia with the t(7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspects.
Biomark Res 2015;3:21.
18. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al.
Pan-cancer genome and transcriptome analyses of 1,699 paediatric
leukaemias and solid tumours. Nature 2018;555:371–6.
19. Pounds S, Cheng C, Li S, Liu Z, Zhang J, Mullighan C. A genomic
random interval model for statistical analysis of genomic lesion data.
Bioinformatics 2013;29:2088–95.
20. Buelow DR, Pounds SB, Wang YD, Shi L, Li Y, Finkelstein D, et al.
Uncovering the genomic landscape in newly diagnosed and relapsed
pediatric cytogenetically normal FLT3-ITD AML. Clin Transl Sci
2019;12:641–7.
21. Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, et al.
Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet 2019;51:694–704.
22. Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, et al.
The genomic landscape of pediatric myelodysplastic syndromes. Nat
Commun 2017;8:1557.
23. Rusch M, Nakitandwe J, Shurtleff S, Newman S, Zhang Z,
Edmonson MN, et al. Clinical cancer genomic profiling by threeplatform sequencing of whole genome, whole exome and transcriptome. Nat Commun 2018;9:3962.
24. Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, et al. The
genomic landscape of core-binding factor acute myeloid leukemias.
Nat Genet 2016;48:1551–6.
25. Newman S, Nakitandwe J, Kesserwan CA, Azzato EM, Wheeler DA,
Rusch M, et al. Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA
sequencing. Cancer Discov 2021;11:3008–27.
26. Corrigan DJ, Luchsinger LL, Justino de Almeida M, Williams LJ,
Strikoudis A, Snoeck HW. PRDM16 isoforms differentially regulate
normal and leukemic hematopoiesis and inflammatory gene signature. J Clin Invest 2018;128:3250–64.
27. Sanij E, Hannan RD. The role of UBF in regulating the structure and
dynamics of transcriptionally active rDNA chromatin. Epigenetics
2009;4:374–82.
206 | BLOOD CANCER DISCOVERY MAY 2022 AACRJournals.org
Downloaded from http://aacrjournals.org/bloodcancerdiscov/article-pdf/3/3/194/3118150/194.pdf by guest on 09 July 2022
We thank all the patients and their families at St. Jude Children’s
Research Hospital (SJCRH) for their contribution of the biological
specimens used in this study. We also thank the Biorepository, the
Flow Cytometry and Cell Sorting Core, and the Hartwell Center
for Bioinformatics and Biotechnology at SJCRH for their essential
services. Julie Justice in the Anatomic Pathology lab established the
IHC for UBTF. This work was funded by the American Lebanese and
Syrian Associated Charities of St. Jude Children’s Research Hospital
and grants from the NIH (P30 CA021765, Cancer Center Support
Grant and a Developmental Fund Award, to J.M. Klco and X. Ma).
This work was also supported in part by the Fund for Innovation in
Cancer Informatics (www.the-ici-fund.org, to X. Ma and J.M. Klco),
St. Baldrick’s Consortium Grant (to S. Meshinchi), Target Pediatric
AML (to S. Meshinchi), Leukemia and Lymphoma Society (6558-18,
to S. Meshinchi), National Institutes of Health (R01-CA114563-10
and HHSN-261200800001E, to S. Meshinchi), COG Chair’s Grant
U10-CA098543 (to S. Meshinchi), Andrew McDonough B+ Foundation (to S. Meshinchi), Hyundai Hope on Wheels (to S. Meshinchi),
NCTN Statistics & Data Center U10-CA180899 (to S. Meshinchi and
T.A. Alonzo), NCTN Operations Center Grant U10CA180886 (to
S. Meshinchi), and Project Stella (to S. Meshinchi). J.M. Klco holds
a Career Award for Medical Scientists from the Burroughs Wellcome Fund and is a previous recipient of the V Foundation Scholar
Award (Pediatric).
Umeda et al.
RESEARCH BRIEF
28. Maiser A, Dillinger S, Langst G, Schermelleh L, Leonhardt H,
Nemeth A. Super-resolution in situ analysis of active ribosomal DNA
chromatin organization in the nucleolus. Sci Rep 2020;10:7462.
29. Tian L, Li Y, Edmonson MN, Zhou X, Newman S, McLeod C, et al.
CICERO: a versatile method for detecting complex and diverse driver
fusions using cancer RNA sequencing data. Genome Biol 2020;21:126.
30. Hagiwara K, Ding L, Edmonson MN, Rice SV, Newman S, Easton J,
et al. RNAIndel: discovering somatic coding indels from tumor RNASeq data. Bioinformatics 2020;36:1382–90.
31. Hagiwara K, Edmonson MN, Wheeler DA, Zhang J. indelPost: harmonizing ambiguities in simple and complex indel alignments. Bioinformatics 2022;38:549–51.
32. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J,
et al. Prognostic relevance of integrated genetic profiling in acute
myeloid leukemia. N Engl J Med 2012;366:1079–89.
33. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL,
et al. Functional genomic landscape of acute myeloid leukaemia.
Nature 2018;562:526–31.
34. Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, et al.
Bortezomib with standard chemotherapy for children with acute
myeloid leukemia does not improve treatment outcomes: a report
from the Children’s Oncology Group. Haematologica 2020;105:
1879–86.
35. Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M,
Klingebiel T, et al. Successes and challenges in the treatment of
pediatric acute myeloid leukemia: a retrospective analysis of the AMLBFM trials from 1987 to 2012. Leukemia 2018;32:2167–77.
36. Klco JM, Spencer DH, Miller CA, Griffith M, Lamprecht TL,
O’Laughlin M, et al. Functional heterogeneity of genetically defined
subclones in acute myeloid leukemia. Cancer Cell 2014;25:379–92.
37. de Boer B, Prick J, Pruis MG, Keane P, Imperato MR, Jaques J, et al.
Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell 2018;34:674–89.
38. Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, DurruthyDurruthy R, et al. Single-cell mutation analysis of clonal evolution in
myeloid malignancies. Nature 2020;587:477–82.
39. Zhou B, Wang J, Lee SY, Xiong J, Bhanu N, Guo Q, et al. PRDM16
suppresses MLL1r leukemia via intrinsic histone methyltransferase
activity. Mol Cell 2016;62:222–36.
40. Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, et al.
High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD,
and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/
Lymphoma Study Group AML-05 trial. Br J Haematol 2016;172:581–91.
41. Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH,
Ramabadran R, et al. Mutant NPM1 maintains the leukemic state
through HOX expression. Cancer Cell 2018;34:499–512.
42. Edmonson MN, Zhang J, Yan C, Finney RP, Meerzaman DM,
Buetow KH. Bambino: a variant detector and alignment viewer for
next-generation sequencing data in the SAM/BAM format. Bioinformatics 2011;27:865–6.
43. Wang J, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, et al.
CREST maps somatic structural variation in cancer genomes with
base-pair resolution. Nat Methods 2011;8:652–4.
44. Chen X, Gupta P, Wang J, Nakitandwe J, Roberts K, Dalton JD, et al.
CONSERTING: integrating copy-number analysis with structuralvariation detection. Nat Methods 2015;12:527–30.
45. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic
landscape of diffuse intrinsic pontine glioma and pediatric nonbrainstem high-grade glioma. Nat Genet 2014;46:444–50.
46. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics
2011;27:2903–4.
47. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H,
Torres-Garcia W, et al. Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun 2013;4:2612.
48. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al.
The ensembl variant effect predictor. Genome Biol 2016;17:122.
49. Edmonson MN, Patel AN, Hedges DJ, Wang Z, Rampersaud E,
Kesserwan CA, et al. Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and
classifying germline variants. Genome Res 2019;29:1555–65.
50. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al.
VarScan 2: somatic mutation and copy number alteration discovery
in cancer by exome sequencing. Genome Res 2012;22:568–76.
51. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a
joint consensus recommendation of the American College of Medical
Genetics and Genomics and the Association for Molecular Pathology.
Genet Med 2015;17:405–24.
52. Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL,
Biesecker LG, et al. Recommendations for interpreting the loss of
function PVS1 ACMG/AMP variant criterion. Hum Mutat 2018;
39:1517–24.
53. Lee K, Krempely K, Roberts ME, Anderson MJ, Carneiro F, Chao E,
et al. Specifications of the ACMG/AMP variant curation guidelines
for the analysis of germline CDH1 sequence variants. Hum Mutat
2018;39:1553–68.
54. Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, et al.
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Adv 2019;3:
2962–79.
55. Gelb BD, Cave H, Dillon MW, Gripp KW, Lee JA, Mason-Suares H,
et al. ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation. Genet Med 2018;20:1334–45.
56. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J,
Wang Q, et al. The mutational constraint spectrum quantified from
variation in 141,456 humans. Nature 2020;581:434–43.
57. Storey JD. A direct approach to false discovery rates. J R Stat Soc
Series B Stat Methodol 2002;64:479–98.
58. Pounds S, Cheng C. Robust estimation of the false discovery rate.
Bioinformatics 2006;22:1979–87.
59. Casella G, Berger RL. Statistical Inference Vol. 70. Belmont, CA:
Duxbury Press; 1990.
60. Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced
mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood 2020;135:41–55.
61. Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M,
et al. Rise and fall of subclones from diagnosis to relapse in pediatric
B-acute lymphoblastic leukaemia. Nat Commun 2015;6:6604.
62. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 2018;34:3094–100.
63. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast,
scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011;7:539.
64. Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with
high-throughput sequencing data. Bioinformatics 2015;31:166–9.
65. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package
for removing batch effects and other unwanted variation in highthroughput experiments. Bioinformatics 2012;28:882–3.
66. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma
powers differential expression analyses for RNA-sequencing and
microarray studies. Nucleic Acids Res 2015;43:e47.
67. Maaten LVD, Hinton GE. Visualizing Data using t-SNE. J Mach Learn
Res 2008;9:2579–605.
68. Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG,
et al. Dimensionality reduction for visualizing single-cell data using
UMAP. Nat Biotechnol 2019;37:38–44.
69. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL,
Gillette MA, et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc Natl
Acad Sci U S A 2005;102:15545–50.
MAY 2022 BLOOD CANCER DISCOVERY | 207
Downloaded from http://aacrjournals.org/bloodcancerdiscov/article-pdf/3/3/194/3118150/194.pdf by guest on 09 July 2022
UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
...
論文の公開元へ
